Thrombosis Drugs Market Size to Gain Traction of US$ 47,000 Million, Growth Opportunities by 2026

According to the new report, the global 𝐭𝐡𝐫𝐨𝐦𝐛𝐨𝐬𝐢𝐬 𝐝𝐫𝐮𝐠𝐬 market was valued at approximately US$ 20,000 Mn in 2017. It is projected to expand at a CAGR of more than 9.5% from 2018 to 2026.

The report suggests that the rise in geriatric population, which is more susceptible to thrombosis events, globally, is likely to boost the demand for thrombosis drugs during the forecast period. North America and Europe are likely to dominate the global thrombosis drugs market due to increase in awareness and rise in focus of key players on the development of new drugs in the market in these regions. Increasing penetration and rising prevalence of thrombosis events in emerging markets such as Japan, Hong Kong, and Taiwan are likely to boost the thrombosis drugs market in Asia Pacific at a CAGR of 9.0% from 2018 to 2026.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐚 𝐬𝐚𝐦𝐩𝐥𝐞 𝐨𝐟 𝐭𝐡𝐢𝐬 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐫𝐞𝐩𝐨𝐫𝐭 𝐚𝐭 (𝐔𝐬𝐞 𝐂𝐨𝐫𝐩𝐨𝐫𝐚𝐭𝐞 𝐌𝐚𝐢𝐥 𝐈𝐝 𝐟𝐨𝐫 𝐐𝐮𝐢𝐜𝐤 𝐑𝐞𝐬𝐩𝐨𝐧𝐬𝐞) - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=46293

𝐄𝐱𝐩𝐚𝐧𝐬𝐢𝐨𝐧 𝐨𝐟 𝐭𝐡𝐞 𝐆𝐞𝐧𝐞𝐫𝐢𝐜 𝐃𝐫𝐮𝐠𝐬 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐭𝐨 𝐇𝐚𝐦𝐩𝐞𝐫 𝐭𝐡𝐞 𝐌𝐚𝐫𝐤𝐞𝐭

The generic drugs industry has witnessed significant expansion in the last few years. Branded drugs of molecule such as heparin consistently lose market share due to the availability and continuous launch of generic version of the drugs. For example, recently, in January 2018, Aurobindo Pharma launched fondaparinux sodium injection, a generic version of Arixtra brand, which is utilized to prevent deep vein thrombosis, after its patent expired.

𝐋𝐨𝐰 𝐌𝐨𝐥𝐞𝐜𝐮𝐥𝐚𝐫 𝐖𝐞𝐢𝐠𝐡𝐭 𝐇𝐞𝐩𝐚𝐫𝐢𝐧 𝐭𝐨 𝐋𝐨𝐬𝐞 𝐌𝐚𝐫𝐤𝐞𝐭 𝐒𝐡𝐚𝐫𝐞

The report offers detailed segmentation of global thrombosis drugs market based on drug class, indication, and distribution channel. Based on drug class, the factor Xa inhibitor drugs segment is estimated to account for a large share of the global market by the end of the forecast period. This is due to the increase in utilization of factor Xa inhibitor drugs for their advantages such as no drug monitoring is required after intake. Moreover, several studies have proved that factor Xa inhibitor drugs are effective in both deep vein thrombosis and pulmonary embolism and help reduce the rate of hospitalization after usage. The low molecular weight heparin segment is anticipated to lose market share during the forecast period, and is expected to decline from 14.7% held in 2017 to reach 5.9% by 2026. Patent expiry, availability of generic drugs, and increased preference toward oral formulation of drugs from injectable dose are factors that are likely to hamper this segment.

𝐁𝐮𝐲 𝐭𝐡𝐢𝐬 𝐏𝐫𝐞𝐦𝐢𝐮𝐦 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭 | 𝐈𝐦𝐦𝐞𝐝𝐢𝐚𝐭𝐞 𝐃𝐞𝐥𝐢𝐯𝐞𝐫𝐲 𝐀𝐯𝐚𝐢𝐥𝐚𝐛𝐥𝐞 𝐚𝐭 - https://www.transparencymarketresearch.com/checkout.php?rep_id=46293<ype=S

𝐏𝐮𝐥𝐦𝐨𝐧𝐚𝐫𝐲 𝐄𝐦𝐛𝐨𝐥𝐢𝐬𝐦: 𝐓𝐨𝐩 𝐈𝐧𝐝𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐓𝐡𝐫𝐨𝐦𝐛𝐨𝐬𝐢𝐬 𝐃𝐫𝐮𝐠𝐬

In terms of indication, the pulmonary embolism segment is projected to hold for a dominant share of the global thrombosis drugs market by the end of the forecast period. The segment is likely to expand at a CAGR more than 10.0% from 2018 to 2026. Most companies are focused on developing low-cost drugs to serve the large pulmonary embolism patients pool across the globe; therefore, the pulmonary embolism segment is likely to account for a dominant share of the market. For example, the U.K-based pharmaceutical company, AstraZeneca, is developing a drug candidate called Brilliant Thales for the indication of cardiovascular events. The atrial fibrillation segment accounted for more than 27.0% share of the global thrombosis drugs market, in terms of value, in 2017. It is anticipated to expand at a substantial pace during the forecast period. The segment is likely to gain market share marginally to reach 27.8% by 2026.

𝐓𝐡𝐞 𝐌𝐚𝐫𝐤𝐞𝐭 𝐢𝐧 𝐍𝐨𝐫𝐭𝐡 𝐀𝐦𝐞𝐫𝐢𝐜𝐚 𝐭𝐨 𝐄𝐱𝐩𝐚𝐧𝐝 𝐚𝐭 𝐚 𝐂𝐨𝐧𝐬𝐢𝐝𝐞𝐫𝐚𝐛𝐥𝐞 𝐏𝐚𝐜𝐞 𝐚𝐧𝐝 𝐂𝐫𝐞𝐚𝐭𝐞 𝐈𝐧𝐜𝐫𝐞𝐦𝐞𝐧𝐭𝐚𝐥 𝐎𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐲

In terms of value, North America held a major share of the global market in 2017. This is due to the high health care expenditure and rise in awareness about the advantages of new oral anticoagulant drugs formulation in the U.S. Furthermore, several players such as Johnson & Johnson and Exithera Pharmaceutical have increased investment in research & development to develop advanced drugs to treat thrombosis. Thus, the presence of these players is projected to propel the thrombosis drugs market in North America at a rapid pace during the forecast period. Increase in incidence of age-related chronic conditions such as cancer and neurological illnesses increases thrombosis events in Asia Pacific. Moreover, improving economic conditions, rise in spending power, and better access to health care service fuels the market in Asia Pacific. Economic growth in countries such as Brazil is increasing research & development activities and expenditure on treatment in Latin America. These factors are likely to propel the thrombosis drugs market in Latin America. It is expected to expand at a CAGR of 9.0% from 2018 to 2026.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐜𝐮𝐬𝐭𝐨𝐦𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐭𝐡𝐢𝐬 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐫𝐞𝐩𝐨𝐫𝐭 𝐚𝐭 - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=46293

𝐁𝐚𝐲𝐞𝐫 𝐀𝐆, 𝐀𝐬𝐩𝐞𝐧 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐚𝐫𝐞 𝐇𝐨𝐥𝐝𝐢𝐧𝐠𝐬 𝐋𝐢𝐦𝐢𝐭𝐞𝐝, 𝐚𝐧𝐝 𝐁𝐨𝐞𝐡𝐫𝐢𝐧𝐠𝐞𝐫 𝐈𝐧𝐠𝐞𝐥𝐡𝐞𝐢𝐦 𝐆𝐦𝐛𝐇 𝐭𝐨 𝐃𝐨𝐦𝐢𝐧𝐚𝐭𝐞 𝐭𝐡𝐞 𝐌𝐚𝐫𝐤𝐞𝐭

The report also provides profiles of leading players operating in the global thrombosis drugs market. These include GlaxoSmithKline plc, Baxter International Inc., Johnson & Johnson, Sanofi, Bristol-Myers Squibb Company, AstraZeneca plc, and Pfizer, Inc. Expansion of product portfolio through developing new products or by acquisition and licensing agreement to develop products is a key strategy adopted by several key players. For instance, in 2015, Isis Pharmaceuticals, Inc., entered into an exclusive license agreement with Bayer HealthCare to develop and commercialize ISIS-FXIRx for the prevention of thrombosis. Other key players are also adopting such strategies.

𝐁𝐫𝐞𝐚𝐬𝐭 𝐏𝐮𝐦𝐩𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 - https://www.globenewswire.com/news-release/2022/03/15/2402991/0/en/Breast-Pumps-Market-to-Advance-at-CAGR-of-10-4-during-2019-2027-Recommendations-on-Meeting-Individual-Needs-of-Mothers-to-Improve-Effectiveness-TMR-Study.html

𝐃𝐞𝐞𝐩 𝐁𝐫𝐚𝐢𝐧 𝐒𝐭𝐢𝐦𝐮𝐥𝐚𝐭𝐢𝐨𝐧 𝐃𝐞𝐯𝐢𝐜𝐞𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 - https://www.prnewswire.com/news-releases/deep-brain-stimulation-devices-market-to-rise-with-increase-in-prevalence-of-neurological-disorders-globally-states-tmr-study-301529264.html

𝐀𝐛𝐨𝐮𝐭 𝐔𝐬 𝐓𝐫𝐚𝐧𝐬𝐩𝐚𝐫𝐞𝐧𝐜𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.

Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.

𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐔𝐬

Nikhil Sawlani
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

This release was published on openPR.